# Dawn J. Caster

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/dawn-j-caster/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,577 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 20 |
| i10-index | 28 |
| Last Known Institution | University of Louisville |
| OpenAlex ID | https://openalex.org/A5038541433 |
| Works | 70 |

## Researcher papers

- [Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-voclosporin-versus-placebo-for-lupus-nephritis-aurora-1-a/)
- [Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-sparsentan-versus-irbesartan-in-patients-with-iga/)
- [Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference](https://scholariq.org/papers/management-and-treatment-of-glomerular-diseases-part-1-conclusions-from-a-kidney/)
- [Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial](https://scholariq.org/papers/sparsentan-in-patients-with-iga-nephropathy-a-prespecified-interim-analysis-from/)
- [Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference](https://scholariq.org/papers/management-and-treatment-of-glomerular-diseases-part-2-conclusions-from-a-kidney/)
- [Safety and Efficacy of <scp>Long‐Term</scp> Voclosporin Treatment for Lupus Nephritis in the Phase 3 <scp>AURORA</scp> 2 Clinical Trial](https://scholariq.org/papers/safety-and-efficacy-of-scp-long-term-scp-voclosporin-treatment-for-lupus/)
- [Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers](https://scholariq.org/papers/identifying-outcomes-important-to-patients-with-glomerular-disease-and-their/)
- [ABIN1 Dysfunction as a Genetic Basis for Lupus Nephritis](https://scholariq.org/papers/abin1-dysfunction-as-a-genetic-basis-for-lupus-nephritis/)
- [Characterization of glomerular extracellular matrix by proteomic analysis of laser-captured microdissected glomeruli](https://scholariq.org/papers/characterization-of-glomerular-extracellular-matrix-by-proteomic-analysis-of/)
- [KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/kdoqi-us-commentary-on-the-2021-kdigo-clinical-practice-guideline-for-the/)
- [Management of Lupus Nephritis: New Treatments and Updated Guidelines](https://scholariq.org/papers/management-of-lupus-nephritis-new-treatments-and-updated-guidelines/)
- [Clinicopathological Characteristics of Adult IgA Nephropathy in the United States](https://scholariq.org/papers/clinicopathological-characteristics-of-adult-iga-nephropathy-in-the-united/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Neutrophil, Myeloperoxidase and Oxidative Mechanisms](https://scholariq.org/topics/neutrophil-myeloperoxidase-and-oxidative-mechanisms/)

## Researcher university

- [University of Louisville](https://scholariq.org/institutions/university-of-louisville/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.